Novartis’ Sandoz chief is walking out in the middle of a global revamp, fueling fresh buzz about a spinoff

The head of Novartis’ big generics division Sandoz has abruptly handed in his walking papers in a move that will immediately reignite speculation that CEO Vas Narasimhan may be prepping a spinoff plan for the struggling group as the parent organization concentrates on developing new drugs.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 50,800+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->